Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

NCT03782259 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Myocardial Fibrosis
Myocardial Inflammation

Interventions

DRUG: dapagliflozin
OTHER: Placebo

Sponsor

University of Washington

Collaborators

[object Object]